Getting latest data loading
Home / Special reports pages / AstraZeneca Page 3

This report is not a personal recommendation and does not take into account your personal circumstances or appetite for risk.

AstraZeneca Page 3

AstraZeneca (AZN)

Will shares rally to pre-Mystic highs of 5000p (+13%) or fall to December lows of 4400p (-10%)?
  • After shares fell 15% on a single day following the Mystic setback, can the shares rally back to pre-trial highs?
  • Relative Strength Index indicator remains stubbornly stuck below 50, regularly seen as a bearish sign
  • Directional indicators diverging bearishly
  • The majority of brokers are positive-leaning, while over 80% expect the price to rise from current level

 

Broker Consensus: 51% Buy, 44% Hold, 5% Sell

Bullish: Societe Generale, Buy, Target 7600p, +71% (1 Aug)

Average Target: 5125p, +16% (18 Aug)

Bearish: HSBC, Reduce, Target 4100p, -7.3% (8 Aug)

 

Pricing and consensus data sourced from Bloomberg on 18 August. Please contact us for a full, up to date rundown.

« Back to Category

This research is produced by Accendo Markets Limited. Research produced and disseminated by Accendo Markets is classified as non-independent research, and is therefore a marketing communication. This investment research has not been prepared in accordance with legal requirements designed to promote its independence and it is not subject to the prohibition on dealing ahead of the dissemination of investment research. This research does not constitute a personal recommendation or offer to enter into a transaction or an investment, and is produced and distributed for information purposes only.

Accendo Markets considers opinions and information contained within the research to be valid when published, and gives no warranty as to the investments referred to in this material. The income from the investments referred to may go down as well as up, and investors may realise losses on investments. The past performance of a particular investment is not necessarily a guide to its future performance. Prepared by Michael van Dulken, Head of Research

Comments are closed.

Spread bets and CFDs are complex instruments and come with a high risk of losing money rapidly due to leverage.
Spread bets and CFDs are complex instruments and come with a high risk of losing money rapidly due to leverage. 67% of retail investor accounts lose money when spread betting and/or trading CFDs with this provider. You should consider whether you understand how spread bets and CFDs work and whether you can afford to take the high risk of losing your money.
.